Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Oral Semaglutide

OASIS 3

Novo Nordisk · Phase 3 · Completed · Enrollment 200

NCT05890976

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 50 mgn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r

Not shown

  • Semaglutide 50 mg: endpoint not reported
  • Semaglutide Placebo: endpoint not reported